New video just out on youtube for the presentation that Bill gave at the recent Sachs Neuroscience Innovation Forum (link below).
He seemed a bit rusty, but generally a good preso.
Couple of key points I took out of it....
- the final DSMB safety analysis will be “in a month or two”
- confident that the efficacy design is appropriate based on the first DSMB analysis
- full results reading out in “May/June”
- they’ve been approached by others for additional indications using xanamem
- current target market for mild Alzheimer’s is US$7.5B based on 1.5m patients. Bill alludes to the upside if you include Prodromol and At Risk markets which have numbers of 4m and 25m, respectively. Even penetrating only 10% of those markets would be massive given that there are almost 20 times more potential users than mild AD.
- Forums
- ASX - By Stock
- ACW
- Sachs Forum Presentation Video
Sachs Forum Presentation Video
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $103.0M |
Open | High | Low | Value | Volume |
4.0¢ | 4.0¢ | 3.7¢ | $121.2K | 3.184M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 3003984 | 3.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.8¢ | 342934 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 3003984 | 0.037 |
5 | 1463388 | 0.036 |
5 | 1066500 | 0.035 |
1 | 250000 | 0.034 |
2 | 210058 | 0.033 |
Price($) | Vol. | No. |
---|---|---|
0.038 | 342934 | 4 |
0.039 | 676366 | 2 |
0.040 | 343376 | 6 |
0.041 | 1051854 | 5 |
0.042 | 347313 | 5 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |